Desmoid fibromatosis: is treatment always necessary?
Desmoid fibromatosis can infiltrate local tissues and cause significant problems, but it does not metastasise like a conventional malignant sarcoma. For many patients, modern care begins with active surveillance.
Short answer
Immediate treatment is not always necessary. Active surveillance is often appropriate when there are no critical symptoms or threats to function. Treatment is considered for persistent progression, increasing symptoms, functional risk or a critical anatomical location.
What active surveillance means
Surveillance is an organised plan, not neglect. It combines symptom review with repeat imaging. Early reassessment may be performed after approximately 8–12 weeks, after which intervals can be adjusted to the tumour’s behaviour and the patient’s situation.
When active treatment may be considered
- documented, persistent growth on serial imaging;
- pain or other symptoms that meaningfully affect daily life;
- threat to nerves, vessels, organs or function;
- a location where further growth would make treatment more difficult.
Surgery can be reasonable in selected resectable tumours when morbidity is acceptable, including some anterior abdominal-wall lesions. Other options may include systemic therapy or radiotherapy in carefully selected situations. Drug availability in Ukraine must be checked at the time treatment is prescribed.
Key point: one MRI shows size and anatomy; serial assessment shows behaviour. The decision should balance tumour control, symptoms and treatment-related harm.